Membranous Nephropathy (MN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Membranous Nephropathy Emerging Therapy and TPP Insights

Thelansis’s “Membranous Nephropathy (MN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Membranous Nephropathy Overview

Membranous nephropathy (MN) is an autoimmune glomerular disease in which antibodies against podocyte antigens, most often PLA2R, trigger immune deposits and complement-mediated injury. It may be primary or associated with infections, autoimmune disease, medicines or malignancy. Proteinuria, low serum albumin and edema are common; nephrotic syndrome raises the risk of thrombosis and infection. Diagnosis uses anti-PLA2R testing, kidney biopsy when indicated, and evaluation for secondary causes. Management starts with blood-pressure and proteinuria control, usually using renin–angiotensin system blockade, plus risk-based monitoring. Patients at risk of progression may receive rituximab, cyclophosphamide with glucocorticoids or calcineurin inhibitors. In Phase III MAJESTY, obinutuzumab achieved higher complete-remission rates than tacrolimus and is under FDA priority review for primary MN; it is not yet approved for this indication. B-cell and plasma-cell targeting remain active research areas.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)